Skip to content

Disc Medicine

US · IRON #2647 by market cap Listed 1970
75.14 -0.97 -1.27%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Price chart

Pre-market 75.12 -1.30%
After-hours 75.14 0.00%
87.0855.7475.142026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on IRON?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -10.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 15.5% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -35.9% Better than 11%
Return on invested capital -37.0% Better than 8%
Momentum B-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -5.9% Better than 60%
6-month return 12.5% Better than 75%
12-month return (ex latest month) -19.0% Better than 15%
Distance below 52-week high 24.5% Better than 52%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 21.9x Better than 98%
Debt to assets 3.8% Better than 82%
Interest coverage -57.7x Better than 7%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 66.4% Better than 74%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -6.07%
1M -5.46%
3M -4.69%
6M +12.10%
YTD -5.38%
1Y -16.83%
3Y +47.02%
5Y -22.46%

Key statistics

Price & volume

Prev close
76.11
Open
75.20
Day range
74.54 - 77.01
Avg price
75.29
Volume
561.65K
Turnover
42.28M
Amplitude
3.25%
52-week range
40.00 - 99.50

Valuation

P/E
-12.50
P/E (TTM)
-11.85
P/B
5.66
EPS
-6.01
Net profit
-273.70M
Net assets
604.24M

Share structure

Market cap
3.42B
Float cap
3.02B
Shares out
45.54M
Float shares
40.15M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 59% of range
40.00 99.50

24.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+3.85M net over the window

Short interest

Shares short
6.86M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Disc Medicine (IRON)?

Disc Medicine last traded at 75.14. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Disc Medicine's market cap?

About 3.42B.

What is the P/E ratio of Disc Medicine?

The trailing twelve-month P/E is -11.85. The Valuation tab shows it against the stock's own five-year range.

Does Disc Medicine pay a dividend?

Disc Medicine does not currently pay a regular dividend.

Is Disc Medicine a buy according to analysts?

The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 125.00, which implies 66.4% upside from the current price. This is not investment advice.

What is Disc Medicine's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Disc Medicine a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:01:18 · For reference only, not investment advice and not tailored to your situation.

Disc Medicine discussion 0 comments

Add a comment